Market Overview

HIV Drugs Market is projected to achieve a value of USD 23,370 Million in 2023, with a linear behavior in the market growth it is forecasted to achieve a value of USD 32,140 Million by 2033 with a CAGR of 3.90% during the forecast period 2023-2033.

Human Immunodeficiency Virus Drugs are related with the treatment of HIV. Human Immunodeficiency Virus (HIV) is a virus that responsible for the condition known as Acquired Immunodeficiency Syndrome (AIDS). Human Immunodeficiency Virus (HIV) is the infection of virus which attacks the body’s immune system which helps to fight against the infection, specifically the CD4 cells also called as T cells, which help to fight against infections in the body.

Human Immunodeficiency Virus Drugs which assist to stop the multiplication of Human Immunodeficiency Virus, helps to decrease further complications. HIV Drugs markets growth attributed by various factors such as rising HIV patients particularly among youth, unprotected sexual contacts, uses of contaminated or nonsterile syringes to healthy people, lack of understanding about the risk factor.   

For instance, HIV is a major and progressive global public health issue, having recorded 40.4 million lives globally, with an estimated 38.4 million people living with the condition at the end of 2021, according to the WHO (World Health Organization).

Moreover, there is no any permeant treatment option to cure HIV.  Therapeutic treatment which available for this disease enable to increase the lifespan of patient, increase the quality of life and control the progression of disease. In recent years Advancements in Antiretroviral Therapy (ART) have transform the treatment of HIV. The development of combination therapies and Highly Active Antiretroviral Therapy (HAART)have significantly improved patient conditions.

COVID 19 pandemic significantly Impacts on the growth of HIV Drugs market due to worldwide lockdown cause disturbance in Import and export drug supply, focusing towards the COVID 19 testing rather than other diseases.  Because of that reduce new patient enrollment due to lack of diagnostic test. Thus, COVID-19 makes a negative impact on the growth of market.

Market Scope

Report Attributes	Description
Market Size in 2022	USD 22,500 Million
Market Forecast in 2033	USD 32,140 Million
CAGR % 2023-2033	3.90%
Base Year	2022
Historic Data	2016-2022
Forecast Period	2023-2033
Report USP	Production, Consumption, company share, company heatmap, company production capacity, growth factors and more
Segments Covered	Drug Type, End-user
Growth Drivers	The widespread adoption of HAART, a combination of different classes of antiretroviral drugs, has transformed HIV treatment Development of Preventive Medications Antiretroviral Drug Delivery Innovation
Regional Scope	North America, Europe, APAC, South America and Middle East and Africa
Country Scope	U.S.; Canada; U.K.; Germany; France; Italy; Spain; Benelux; Nordic Countries; Russia; China; India; Japan; South Korea; Australia; Indonesia; Thailand; Mexico; Brazil; Argentina; Saudi Arabia; UAE; Egypt; South Africa; Nigeria
Key Companies	Boehringer Ingelheim International GmbH, Cipla Inc., Merck & Co., Inc., AbbVie Inc., Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd, Gilead Sciences, Inc., Hoffmann-La Roche Ltd, Pfizer Inc., Aurobindo Pharma, Celltrion Healthcare Co.,Ltd, ViiV Healthcare.

 Market Dynamics

The HIV Drugs Market is driven by increasing prevalence of HIV patients, factor responsible for increasing prevalence includes lack of awareness of mode of transmission of virus, rise in treatment and diagnosis rate. Moreover, there is a huge escalation of government initiatives to increase awareness about HIV causes, available treatment options, symptoms of diseases.

HIV patients are treated as curing the illness and increasing the quality of life. As such permanent solution is not available yet to cure the HIV and save patient life. A wider use of pre-exposure prophylaxis(PrEP) which is a preventive approach to people who having a high risk of HIV. Pre-exposure prophylaxis(PrEP) is a drug which acts as a catalyst helps the body to produce antibodies, which help to fight against diseases causing germs and viruses.

Increasing the importance of R&D activities and government funding foe research in the field of Human Immunodeficiency Virus Drugs anticipates the growth of the market. Moreover, technological advancement enhances the delivery and long lasting effect of the drugs in HIV. For instance, according to the article March 2020, published by the National Institutes of Health (NIH), long-acting injectable nanoformulations of cabotegravir and rilpivirine used for HIV therapy were in phase III clinical trials. Cabotegravir was in advanced clinical development for HIV pre-exposure prophylaxis, and these formulations are expected to give results equivalent to traditional medicines, thus boosting the growth of HIV drugs market.

Furthermore, the increasing cost of advance therapeutic treatment and devices hamper the growth of the market. For overcome this problems government initiatives helps HIV patients in treatement. For Instance, Indian government run National AIDS control Organization which is a central funded organization to helps HIV patients. 

Overall, with the help of existing and combination treatment therapy the HIV Drugs Market is expected to witness significant growth in the coming years, driven by the introduction of new therapies and an increasing demand for effective treatments. Additionally, there is a need for advance and effective research and development to address the unmet needs of cancer treatment and to develop safe and effective therapies with lower side effects.

Market Drug Type Analysis

By Drug Type, the HIV Drugs Market is Categories into Protease Inhibitors, Fusion Inhibitors, CCR5 Antagonist, Nucleoside, Integrase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors. The T Nucleoside segment accounts for the largest share of around 42% of the Market in 2022.

The Nucleoside Therapy segment dominates the market because the therapeutic improving outcomes of this segment is greater than the other segments in the treatment of HIV and co-infection.

Market End-User Analysis

By End-user, the HIV Drugs Market is Categories into Hospitals & Clinics, Specialty Centers. The Hospital & Clinics segment accounts for the largest share of around 54% of the Market in 2022.

Rising investment in healthcare and increasing hospital facility in developed and developing market are major factor to drive the segment. Moreover, Hospitals are the primary healthcare facility where patient come for treatment. Also hospital having the infrastructure to diagnosis and identified the HIV or co-infection and advance treatment option.

Market Regional Analysis

North America dominate the HIV Drugs Market with the highest revenue generating market with share of more than 43%. The North America dominate this market due to the rising prevalence of HIV in US, easy availability of medications, new products launch. Additionally, strong presence of market player, well developed infra structure, higher number of research favor growth of region.

Europe having the second-largest market share in Market due to the rising demand for targeted medication, focus on R&D on HIV Drugs found in Europe. Moreover, government policies and increasing the elder population in the region significantly contribute to expand the market.

Asia-Pacific is estimated the fastest growing CAGR in HIV Drugs Market in forecasted period. This is due to increasing in healthcare expenditure and the rise in research and development activities in the pharmaceutical sector.

Competitive Analysis

The HIV Drugs Market is dominated by a few large companies, such as Boehringer Ingelheim International GmbH, Cipla Inc., Merck & Co., Inc., AbbVie Inc., Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd, Gilead Sciences, Inc., Hoffmann-La Roche Ltd, Pfizer Inc., Aurobindo Pharma, Celltrion Healthcare Co.,Ltd, ViiV Healthcare

There Are Some Of The Recent Developments Of The HIV Drugs Market:

July 2021 To make darunavir paired with ritonavir (DRV/r) as a second-line medication for HIV patients living in low and medium-income countries, Unitaid and Clinton Health Access Initiative, Inc. (CHAI) announced a pricing agreement with pharmaceutical company Hetero Labs LTD. The price of the deal is US$ 210 per patient per year.

March 2021 An agreement for collaboration to co-develop and co-commercialize long-acting HIV medication was made public by Gilead Sciences Inc. and Merck. To create a two-drug HIV treatment regimen, the firms want to combine lenacapavir, an experimental capsid inhibitor from Gilead, with islatravir, an investigational nucleoside reverse transcriptase translocation inhibitor from Merck.

In Aug 2018, Merck & Co., Inc. announced that FDA approved its two new antiretroviral drugs named Delstrigo & Pifetro that helped in treatment of HIV-1, the most common strain of virus.

By Drug Type

·         Protease Inhibitors

·         Fusion Inhibitors

·         CCR5 Antagonist

·         Nucleosidz

·         Integrase Inhibitors

·         Non-Nucleoside Reverse Transcriptase Inhibitors

·  

By End-User

·         Hospitals & Clinics

·         Specialty Centers

1.      Global HIV Drugs Market Introduction and Market Overview

1.1.    Objectives of the Study

1.2.    Global HIV Drugs Market Scope and Market Estimation

1.2.1. Global HIV Drugs Overall Market Size, Revenue (US$ Mn), Market CAGR (%), Market forecast (2023 - 2033)

1.2.2. Global HIV Drugs Market Revenue Share (%) and Growth Rate (Y-o-Y) from 2019 - 2033

1.3.    Market Segmentation

1.3.1. Component of Global HIV Drugs Market

1.3.2. Technology of Global HIV Drugs Market

1.3.3. End-user of Global HIV Drugs Market

1.3.4. Region of Global HIV Drugs Market

2.      Executive Summary

2.1.    Global HIV Drugs Market Industry Trends under COVID-19 Outbreak

2.1.1. Global COVID-19 Status Overview

2.1.2. Influence of COVID-19 Outbreak on Global HIV Drugs Market Industry Development

2.2.    Market Dynamics

2.2.1. Drivers

2.2.2. Limitations

2.2.3. Opportunities

2.2.4. Impact Analysis of Drivers and Restraints

2.3.    Pricing Trends Analysis & Average Selling Prices (ASPs)

2.4.    Key Mergers & Acquisitions, Expansions, JVs, Funding / VCs, etc.

2.5.    Porter’s Five Forces Analysis

2.5.1. Bargaining Power of Suppliers

2.5.2. Bargaining Power of Buyers

2.5.3. Threat of Substitutes

2.5.4. Threat of New Entrants

2.5.5. Competitive Rivalry

2.6.    Value Chain / Ecosystem Analysis

2.7.    Russia-Ukraine War Impacts Analysis

2.8.    Economic Downturn Analysis

2.9.      Market Investment Opportunity Analysis (Top Investment Pockets), By Segments & By Region

3.      Global HIV Drugs Market Estimates & Historical Trend Analysis (2019 - 2022)

4.      Global HIV Drugs Market Estimates & Forecast Trend Analysis, Drug Type

4.1.    Global HIV Drugs Market Revenue (US$ Mn) Estimates and Forecasts, Drug Type, 2019 to 2033

4.1.1. Protease Inhibitors

4.1.2. Fusion Inhibitors

4.1.3. CCR5 Antagonist

4.1.4. Nucleoside

4.1.5. Integrase Inhibitors

4.1.6. Non-Nucleoside Reverse Transcriptase Inhibitors

5.      Global HIV Drugs Market Estimates & Forecast Trend Analysis, by End-user

5.1.    Global HIV Drugs Market Revenue (US$ Mn) Estimates and Forecasts, by End-user, 2019 to 2033

5.1.1. Hospitals & Clinics

5.1.2. Specialty Centers

6.      Global HIV Drugs Market Estimates & Forecast Trend Analysis, by Region

6.1.    Global HIV Drugs Market Revenue (US$ Mn) Estimates and Forecasts, by Region, 2019 to 2033

6.1.1. North America

6.1.2. Europe

6.1.3. Asia Pacific

6.1.4. Middle East & Africa

6.1.5. South America

7.      North America HIV Drugs Market: Estimates & Forecast Trend Analysis

7.1.    North America HIV Drugs Market Assessments & Key Findings

7.1.1. North America HIV Drugs Market Introduction

7.1.2. North America HIV Drugs Market Size Estimates and Forecast (US$ Million) (2019 – 2033)

7.1.2.1.   Drug Type

7.1.2.2.   By End-user

7.1.2.3.   By Country

7.1.2.3.1.     The U.S.

7.1.2.3.2.     Canada

7.1.2.3.3.     Mexico

8.      Europe HIV Drugs Market: Estimates & Forecast Trend Analysis

8.1.    Europe HIV Drugs Market Assessments & Key Findings

8.1.1. Europe HIV Drugs Market Introduction

8.1.2. Europe HIV Drugs Market Size Estimates and Forecast (US$ Million) (2019 – 2033)

8.1.2.1.   Drug Type

8.1.2.2.   By End-user

8.1.2.3.        By Country

8.1.2.3.1.     Germany

8.1.2.3.2.     U.K.

8.1.2.3.3.     France

8.1.2.3.4.     Italy

8.1.2.3.5.     Spain

8.1.2.3.6.     Russia

8.1.2.3.7.     Rest of Europe

9.      Asia Pacific HIV Drugs Market: Estimates & Forecast Trend Analysis

9.1.    Asia Pacific Market Assessments & Key Findings

9.1.1. Asia Pacific HIV Drugs Market Introduction

9.1.2. Asia Pacific HIV Drugs Market Size Estimates and Forecast (US$ Million) (2019 – 2033)

9.1.2.1.   Drug Type

9.1.2.2.   By End-user

9.1.2.3.        By Country

9.1.2.3.1.     China

9.1.2.3.2.     Japan

9.1.2.3.3.     India

9.1.2.3.4.     Australia

9.1.2.3.5.     South Korea

9.1.2.3.6.     ASEAN

9.1.2.3.7.     Rest of Asia Pacific

10.  Middle East & Africa HIV Drugs Market: Estimates & Forecast Trend Analysis

10.1.  Middle East & Africa Market Assessments & Key Findings

10.1.1.   Middle East & Africa HIV Drugs Market Introduction

10.1.2.   Middle East & Africa HIV Drugs Market Size Estimates and Forecast (US$ Million) (2019 – 2033)

10.1.2.1.    Drug Type

10.1.2.2.    By End-user

10.1.2.3.    By Country

10.1.2.3.1. U.A.E.

10.1.2.3.2. Saudi Arabia

10.1.2.3.3. Egypt

10.1.2.3.4. South Africa

10.1.2.3.5. Rest of Middle East & Africa

11.  South America HIV Drugs Market: Estimates & Forecast Trend Analysis

11.1.  South America Market Assessments & Key Findings

11.1.1.   South America HIV Drugs Market Introduction

11.1.2.   South America HIV Drugs Market Size Estimates and Forecast (US$ Million) (2019 – 2033)

11.1.2.1.    Drug Type

11.1.2.2.    By End-user

11.1.2.3.    By Country

11.1.2.3.1. Brazil

11.1.2.3.2. Argentina

11.1.2.3.3. Colombia

11.1.2.3.4. Rest of South America

12.  Competition Landscape

12.1.  Global HIV Drugs Market Competition Matrix & Benchmarking, by Leading Players / Innovators / Emerging Players / New Entrants

12.2.  Global HIV Drugs Market Competition White Space Analysis, By End-user

12.3.  Global HIV Drugs Market Competition Heat Map Analysis, By End-user

12.4.  Global HIV Drugs Market Concentration & Company Market Shares (%) Analysis, 2022

13.  Company Profiles

13.1.   Boehringer Ingelheim International GmbH.

13.1.1.   Company Overview & Key Stats

13.1.2.   Financial Performance & KPIs

13.1.3.   Product Portfolio

13.1.4.   Business Strategy & Recent Developments

* Similar details would be provided for all the players mentioned below 

14.  Cipla Inc.

15.  Merck & Co., Inc.

16.  AbbVie Inc.

17.  Bristol-Myers Squibb Company

18.  Teva Pharmaceutical Industries Ltd

19.  Gilead Sciences, Inc.

20.  Hoffmann-La Roche Ltd

21.  Pfizer Inc.

22.  Aurobindo Pharma

23.  Celltrion Healthcare Co.,Ltd

24.  ViiV Healthcare.

25.  Research Methodology

25.1.  External Transportations / Databases

25.2.  Internal Proprietary Database

25.3.  Primary Research

25.4.  Secondary Research

25.5.  Assumptions

25.6.  Limitations

25.7.  Report FAQs

26.  Research Findings & Conclusion

Quality Assurance Process

1. We Market Research’s Quality Assurance program strives to deliver superior value to our clients.

We Market Research senior executive is assigned to each consulting engagement and works closely with the project team to deliver as per the clients expectations.

Market Research Process

We Market Research monitors 3 important attributes during the QA process- Cost, Schedule & Quality. We believe them as a critical benchmark in achieving a project’s success.

To mitigate risks that can impact project success, we deploy the follow project delivery best practices:

• Project kickoff meeting with client
• Conduct frequent client communications
• Form project steering committee
• Assign a senior SR executive as QA Executive
• Conduct internal editorial & quality reviews of project deliverables
• Certify project staff in SR methodologies & standards
• Monitor client satisfaction
• Monitor realized value post-project

Case Study- Automotive Sector

One of the key manufacturers of automotive had plans to invest in electric utility vehicles. The electric cars and associated markets being a of evolving nature, the automotive client approached We Market Research for a detailed insight on the market forecasts. The client specifically asked for competitive analysis, regulatory framework, regional prospects studied under the influence of drivers, challenges, opportunities, and pricing in terms of revenue and sales (million units).

Solution

The overall study was executed in three stages, intending to help the client meet its objective of precisely understanding the entire market before deciding on an investment. At first, secondary research was conducted considering political, economic, social, and technological parameters to get a gist of the various aspects of the market. This stage of the study concluded with the derivation of drivers, opportunities, and challenges. It also laid substantial emphasis on understanding and collecting data not only on a global scale but also on the regional and country levels. Data Extraction through Primary Research

The second stage involved primary research in which several market players and automotive parts suppliers were contacted to study their viewpoint concerning the development of their market and production capacity, clientele, and product line. This stage concluded in a brief understanding of the competitive ecosystem and also glanced through the strategies and pricing of the companies profiled.

Market Estimates and Forecast

In the final stage of the study, market forecasts for the electric utility were derived using multiple market engineering approaches. This data helped the client to get an overview of the market and accelerate the process of investment.

Case Study- ICT Sector

Business process outsourcing, being one of the lucrative markets from both supply- and demand- side, has appealed to various companies. One of the prominent corporations based out of Japan approached us with their requirements regarding the scope of the procurement outsourcing market for around 50 countries. Additionally, the client also sought key players operating in the market and their revenue breakdown in terms of region and application.

Business Solution

An exhaustive market study was conducted based on primary and secondary research that involved factors such as labor costs in various countries, skilled and technical labors, manufacturing scenario, and their respective contributions in the global GDP. A comparative study of the market was conducted from both supply- and demand side, with the supply-side comprising of notable companies, such as GEP, Accenture, and others, that provide these services. On the other hand, large manufacturing companies from them demand-side were considered that opt for these services.

Conclusion

The report aided the client in understanding the market trends, including country-level business scenarios, consumer behavior, and trends in 50 countries. The report also provided financial insights of crucial players and detailed market estimations and forecasts till 2033.